.png){kind=small}
.png){kind=small}
BackTable / Tumor Board / Podcast / Episode #44
ESMO Update: Advances in Upper GI Malignancies
with Dr. Jun Gong
The FLOT regimen is the standard-of-care for upper gastroesophageal malignancies, but what if there were other drug combinations or perioperative strategies that could further improve outcomes? In Part II of our ESMO 2025 recap, medical oncologists Dr. Jun Gong and Dr. Jonathan Mizrahi cover emerging studies and treatments in gastroesophageal cancers.
Be part of the conversation. Put your sponsored messaging on this episode. Learn how.
BackTable, LLC (Producer). (2026, January 20). Ep. 44 – ESMO Update: Advances in Upper GI Malignancies [Audio podcast]. Retrieved from https://www.backtable.com
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Synopsis
The discussion provides an overview of pivotal trials, including MATTERHORN, which demonstrated improved overall survival with durvalumab plus FLOT, and FORTITUDE-10, which highlights ongoing challenges in treatment efficacy with FGFR2b inhibitors. This episode also explores the role of lenvatinib-based combinations for esophageal squamous cell carcinoma and practical considerations for integrating checkpoint inhibitors into real-world clinical practice.
Timestamps
00:00 - Introduction
01:23 - The MATTERHORN Study
03:24 - PD-L1 Status and Clinical Implications
07:09 - FORTITUDE-101 and 102 Studies: Discrepancies and Insights on FGFR2b Inhibition
11:15 - LEAP-014 and 015 Studies: The Role of Lenvatinib
14:57 - Conclusion and Final Thoughts
Resources
Phase III MATTERHORN Study
https://dailynews.ascopubs.org/do/matterhorn-durvalumab-chemotherapy-demonstrates-superior-efs-over-standard-care
ESOPEC Phase III Trial
https://pmc.ncbi.nlm.nih.gov/articles/PMC4952147/
FORTITUDE-101 Trial
https://clinicaltrials.gov/study/NCT05052801
FORTITUDE-102 Trial
https://clinicaltrials.gov/study/NCT05111626
LEAP-014 Phase III Study
https://ascopubs.org/doi/10.1200/JCO.2022.40.4_suppl.TPS367
LEAP-015 Study
https://ascopubs.org/doi/10.1200/JCO-25-00748
The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.
Up Next
